Medication Risk Management for Long-Term Care
Pharmacogenomics is the study of drug-genome interactions and their clinical implications. This form of precision medicine looks for genetic markers that indicate how a resident might respond to a drug.
More than 2 million prescriptions in the U.S. result in an adverse reaction because response rates vary.
Pharmacogenomic risk assessments and testing can help facilities and providers identify, monitor, and manage potential issues associated with resident medications.
Benefits to Skilled Nursing Facilities
- Fewer adverse drug events
- Increased cost savings
- Better outcomes
Today, there are more than 450 medications whose use is improved by understanding a resident’s genetic makeup based on FDA drug labels.
A simple DNA test can reveal how a resident’s body metabolizes a specific drug compound to enable the care team to customize treatment and calculate optimal dosing.
PharMerica’s consultant pharmacists can review the DNA test results and evaluate whether they are useful in determining therapeutic treatment.
Most insurance companies used by long-stay residents, including Medicare Part D and Medicaid plans, cover the cost of this testing for eligible members.
PharMerica has a longstanding partnership with AccessDx Laboratory, a nationwide expert in LTPACs and provider of precision medicine solutions, to offer pharmacogenomic risk assessments and testing to help facilities and providers identify, monitor, and manage potential issues associated with resident medications. Contact your account manager for more information.